HPV testing is an efficient management choice for women with inadequate liquid-based cytology in cervical cancer screening.

This study compares colposcopy referrals of 2 management strategies: oncogenic human papillomavirus (HPV)-DNA testing (Hybrid Capture 2 assay, Qiagen, Germantown, MD) and repeat cytology. In the New Technology in Cervical Cancer Trial, 22,708 subjects were randomly assigned to undergo both HPV and liquid-based cytologic testing. Women aged 35 to 60 years old with unsatisfactory cytologic findings were directly referred for colposcopy if the HPV test result was positive, and were referred for repeat cytologic examination if the HPV test result was negative; women aged 25 to 35 years old were referred for repeat cytologic examination independent of HPV test results. A positive or a second unsatisfactory cytologic examination referred women for colposcopy. Five hundred sixty women had unsatisfactory cytologic findings. Colposcopy referral was not significant and slightly higher with HPV testing than repeat cytologic test (9.8% vs 6.8%, P = .11). When cytologic testing was repeated 36.8% were unavailable for follow-up and most of the colposcopies were performed in HPV-negative women. For unsatisfactory cytologic findings, HPV triage is a more logical and efficient management strategy than a repeat cytologic test.

[1]  C. Magnani,et al.  [Results and cost evaluation of triage with high risk HPV test in cervical cancer screening. A pilot study in Piedmont (North-West Italy)]. , 2012, Epidemiologia & Prevenzione.

[2]  Gabriella Guasticchi,et al.  Distribution of high and low risk HPV types by cytological status: a population based study from Italy , 2011, Infectious Agents and Cancer.

[3]  M. Desai,et al.  Accuracy of liquid‐based cytology , 2010, Cancer cytopathology.

[4]  G. Ronco,et al.  Age‐specific patterns of unsatisfactory results for conventional Pap smears and liquid‐based cytology: data from two randomised clinical trials , 2010, BJOG : an international journal of obstetrics and gynaecology.

[5]  S. Ciatto,et al.  Risk of CIN2 in Women With a Pap Test Without Endocervical Cells vs. Those With a Negative Pap Test With Endocervical Cells , 2010, Acta Cytologica.

[6]  J. Cuzick,et al.  Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. , 2010, The Lancet. Oncology.

[7]  J. Peto,et al.  ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening. , 2009, Health technology assessment.

[8]  C. Clar,et al.  The clinical effectiveness of glucosamine and chondroitin supplements in slowing or arresting progression of osteoarthritis of the knee: a systematic review and economic evaluation. , 2009, Health technology assessment.

[9]  P. Sparén,et al.  Process performance of cervical screening programmes in Europe. , 2009, European journal of cancer.

[10]  G. Collina,et al.  The reproducibility of CIN diagnoses among different pathologists: data from histology reviews from a multicenter randomized study. , 2009, American journal of clinical pathology.

[11]  P Barton,et al.  Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care. , 2009, Health technology assessment.

[12]  Chengquan Zhao,et al.  High-Risk Human Papillomavirus DNA Test Results Are Useful for Disease Risk Stratification in Women With Unsatisfactory Liquid-Based Cytology Pap Test Results , 2009, Journal of lower genital tract disease.

[13]  L. Irwig,et al.  HPV testing versus repeat Pap testing for the management of a minor abnormal Pap smear: evaluation of a decision aid to support informed choice. , 2008, Patient education and counseling.

[14]  Chengquan Zhao,et al.  Adjunctive high‐risk human papillomavirus DNA testing is a useful option for disease risk assessment in patients with negative Papanicolaou tests without an endocervical/transformation zone sample , 2008, Cancer.

[15]  J. Cuzick,et al.  Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. , 2008, Journal of the National Cancer Institute.

[16]  Marc Arbyn,et al.  Liquid Compared With Conventional Cervical Cytology: A Systematic Review and Meta-analysis , 2008, Obstetrics and gynecology.

[17]  Chengquan Zhao,et al.  Human papillomavirus DNA detection in ThinPrep Pap test vials is independent of cytologic sampling of the transformation zone. , 2007, Gynecologic oncology.

[18]  A. Bondi,et al.  Interlaboratory reproducibility of liquid‐based equivocal cervical cytology within a randomized controlled trial framework , 2007, Diagnostic cytopathology.

[19]  J. Cuzick,et al.  Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening: randomised controlled trial , 2007, BMJ : British Medical Journal.

[20]  M. Zorzi,et al.  Extension of organised cervical cancer screening programmes in Italy and their process indicators. , 2007, Epidemiologia e prevenzione.

[21]  J. Cuzick,et al.  HPV triage for low grade (L-SIL) cytology is appropriate for women over 35 in mass cervical cancer screening using liquid based cytology. , 2007, European journal of cancer.

[22]  J. Cuzick,et al.  Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. , 2006, The Lancet. Oncology.

[23]  J. Cuzick,et al.  Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. , 2006, Journal of the National Cancer Institute.

[24]  W. Lawrence,et al.  Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion Triage Study (ALTS). , 2006, Journal of the National Cancer Institute.

[25]  A. Tos,et al.  Reproducibility of HPV DNA Testing by Hybrid Capture 2 in a Screening Setting. , 2005, American journal of clinical pathology.

[26]  Allan M. Seidenfeld,et al.  Results of the implementation of liquid‐based cytology—SurePath in the Ontario screening program , 2004, Cancer.

[27]  Joan L. Walker A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. , 2003, American journal of obstetrics and gynecology.

[28]  J. T. Cox,et al.  Effects of age and human papilloma viral load on colposcopy triage: data from the randomized Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS). , 2002, Journal of the National Cancer Institute.

[29]  C. De Marco,et al.  [Smoking in car: monitoring pollution of particulate matter, of organic volatile compounds and of carbon monoxide. The effect of opening the driver's window]. , 2010, Epidemiologia e prevenzione.

[30]  M. Bibbo,et al.  The revised Bethesda System for reporting cervical/vaginal cytologic diagnoses: report of the 1991 Bethesda workshop. , 1992, The Journal of reproductive medicine.